Sagimet Biosciences Inc. Series A Common Stock

SGMTNASDAQ • USD
10.17 USD
↘ 0.05 (0.49%)🟢LIVE (AS OF 01:48 PM EST)
🟢Market: OPEN

SGMT is currently priced at $10.17. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, SGMT trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 13, 2026.

Open?$10.10
High?$10.43
Low?$9.15
Prev. Close?$10.22
Volume?305.4K
Avg. Volume?1.2M
VWAP?$10.25
Rel. Volume?0.26x
Bid / Ask
Bid?$10.18 × 300
Ask?$10.23 × 100
Spread?$0.05
Midpoint?$10.21
Valuation & Ratios
Market Cap?735.2M
Shares Out?71.4M
Float?61.7M
Float %?88.2%
P/E Ratio?N/A
P/B Ratio?3.04
EPS?-$0.74
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Employees
16
Market Cap
735.2M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2023-07-14
Address
950 TOWER LANE
FOSTER CITY, CA 94404
Phone: (650) 561-8600
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
34
Piotroski F-Score?0/9Weak
Altman Z-Score?9.28Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?19.72%High
Short Interest?12.2M
Days to Cover?10.5
Free Float61.7M
Avg Daily Volume1.2M
Settlement Date2026-10-30
Financial Health
Current Ratio?6.34Strong
Quick Ratio?6.34Strong
Cash Ratio?2.92Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
55
3.04FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-10.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
7
-22.0%WEAK▾
ROA?
S&P
3
-18.9%WEAK▾
Cash Flow & Enterprise
FCF?$-43655000
Enterprise Value?$624.2M
Fundamentals ratios updated end of day